Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 191.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,389,405 shares of the medical equipment provider’s stock after purchasing an additional 913,310 shares during the period. Nuveen Asset Management LLC’s holdings in Zimmer Biomet were worth $146,763,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ZBH. Stonebridge Financial Group LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at $25,000. Accredited Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth $36,000. Kentucky Trust Co purchased a new stake in Zimmer Biomet in the 4th quarter valued at approximately $39,000. OFI Invest Asset Management acquired a new position in Zimmer Biomet during the fourth quarter worth $40,000. Finally, Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 86.6% in the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 206 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.39% of the company’s stock.

Analyst Ratings Changes

ZBH has been the subject of several research reports. Morgan Stanley reduced their price objective on Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. JMP Securities decreased their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lowered their price target on Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Royal Bank of Canada dropped their price objective on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. Finally, BTIG Research reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $113.45.

Zimmer Biomet Trading Up 1.4%

NYSE ZBH opened at $96.68 on Friday. The company has a market capitalization of $19.13 billion, a price-to-earnings ratio of 21.73, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The company’s fifty day moving average price is $103.62 and its two-hundred day moving average price is $105.92. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.92 and a 12 month high of $122.17.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.89 billion. During the same period last year, the business posted $1.94 earnings per share. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.99%. Zimmer Biomet’s payout ratio is currently 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.